

MRN: _____

DOB: _____

STANDARD Orencia® (abatacept) PLAN OF TREATMENT FOR RHEUMATOLOGY

NOTE: Patient may be ineligible to receive abatacept if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new or worsening diagnosis of COPD or respiratory status, and/or surgery.

1. Patient Name: _____ Height (inches): _____ Weight (lbs): _____

2. Allergies: _____

3. **Diagnosis:** * Please complete the 2nd and 3rd digits to complete the ICD-10 code for billing

M05. _____ Rheumatoid Arthritis with Rheumatoid factor M06. _____ Rheumatoid Arthritis without Rheumatoid factor

Other ICD-10 Code: _____ Diagnosis description: _____

4. **Pre-medications:** None OR Administered 30 minutes prior to infusion as selected:

***Product information does not suggest premedication and suggest caution with use of Diphenhydramine due to 30 minute infusion time and safety risks with driving.**

a) Acetaminophen: <input type="checkbox"/> 650mgs PO <input type="checkbox"/> 500mgs PO <input type="checkbox"/> 325mgs PO	b) Diphenhydramine: <input type="checkbox"/> 25 mgs PO, <input type="checkbox"/> 50mgs PO, <input type="checkbox"/> 25 mgs IVP, <input type="checkbox"/> 50mgs IVP or c) Alternate oral antihistamine to diphenhydramine: <input type="checkbox"/> Cetirizine 10 mg, <input type="checkbox"/> Loratadine 10 mg, Fexofenadine <input type="checkbox"/> 60mgs or <input type="checkbox"/> 180mgs d) Other: Methylprednisolone <input type="checkbox"/> 40mgs IVP <input type="checkbox"/> 125mgs IVP or other _____mgs IVP Famotidine: <input type="checkbox"/> 20mgs PO, <input type="checkbox"/> 40mgs PO, <input type="checkbox"/> 20mgs IVP, <input type="checkbox"/> 40mgs IVP
---	---

e) Pre-medicate with other: _____

Orders: Obtain weight each visit. **Vital signs at baseline and after completion, then may discharge when infusion is complete.** Instruct patient/caregiver on medications and signs/symptoms of adverse reaction. Assess patient for response to therapy. Utilize existing central line for administration or initiate a peripheral IV with each infusion as needed. Sodium Chloride 0.9% flush 3-10 ml before, after, and as needed during the infusion. Follow infusion with Heparin 100 units/ml 1 – 5 ml per line type or to peripheral IV as required for multiple day treatments. Pump, tubing, 0.22 micron filter, and supplies needed to include silicone-free syringe for reconstitution to complete prescribed therapy. Pharmacist to perform clinical drug monitoring. **If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES.**

5. **Dose:** Orencia® (abatacept) dosage per 100 ml Sodium Chloride 0.9% IV to infuse over at least 30 minutes.

Body Weight of Patient	Dose	Number of 250mg (abatacept) Vials
< 60 kg	500 mg	2
60 to 100 kg	750 mg	3
>100 kg	1000 mg	4

6. **Frequency:** _____ Induction orders to be completed at 0 week, 2 week, and 4 weeks, and then every 4 weeks thereafter
_____ Orders every 4 weeks (maintenance).
_____ Special Orders: _____

Lab orders with infusions: _____

7. **Physician's Signature:** _____ / _____ Date: _____

No Stamp Signatures

(Dispense as written)

(Substitution permitted)

Printed Physician's Name with Credentials: _____

MRN: _____

DOB: _____

Guidelines for Prescribing Orenzia® (abatacept) for Rheumatology

(Required documentation with all initial referrals)

Patient Name: _____

Referral Date: _____

___ Include signed and completed **Plan of Treatment**.

___ Include patient demographic information and insurance information. (Copy of insurance cards if available)

___ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

- Orenzia® is indicated for moderately to severely active RA in adults. ORENZIA may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists.

___ If patient is switching biological therapies, then MD must specify wash-out period prior to starting Orenzia® as specified of _____ weeks. Last known biological therapy: _____ and last date received: _____. (Include copy of last Orenzia® infusion record if available and currently on therapy)

___ Other as requested: _____

Pre-Screening:

___ **Required TB screening results: PPD or QuantiFERON Gold Test.**

(* If screening results are positive or indeterminate, then a negative CXR result is required.)

___ **Required Hepatitis screening to include: Hepatitis B Surface Antigen results.**

** Warnings/Precautions: Patient should not have an active ongoing infection, signs or symptoms of malignancy, or invasive fungal infection. **COPD patients** may develop more frequent respiratory adverse events. Orenzia® in patients with RA and COPD should be undertaken with caution and such patients should be monitored for worsening of their respiratory status. **Blood Glucose Monitoring:** Orenzia® contains maltose and can interfere with the readings of blood glucose monitors that use test strips with (GDH-PQQ), resulting in falsely elevated blood glucose readings on the day of infusion. **Hepatitis B Reactivation:** Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop Orenzia® and begin anti-viral therapy. Evaluation of immunizations should be completed prior to and **live vaccines** should not be given before or concurrently with Orenzia®. See full prescribing information.



Checklist for referrals to AccuRX Infusion Center:

Fax referral to 1-866-990-3192

- Patient demographics – address, phone number, SS#, etc.
- Insurance Information – copy of the card(s) if possible
- Plan of Treatment/Orders
- Most recent physician office notes to include tried and failed therapies – all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs
- Any lab results or other diagnostic procedures to support the diagnosis

AccuRx Infusion Center will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.